References

Respiratory syncytial virus infection in elderly and high-risk adults

10.1056/nejmoa043951 · 2005 · External reference

The burden of respiratory infections among older adults in long-term care: a systematic review

10.1186/s12877-019-1236-6 · 2019 · External reference

Human metapneumovirus: a new respiratory pathogen

10.1007/s12038-008-0067-y · 2008 · External reference

Epidemiology of human metapneumovirus

10.1128/cmr.00014-06 · 2006 · External reference

Human metapneumovirus - what we know now

10.12688/f1000research.12625.1 · 2018 · External reference

Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis

10.1016/s0140-6736(22)00478-0 · 2022 · External reference

Global burden of acute lower respiratory infection associated with human metapneumovirus in children under 5 years in 2018: a systematic review and modelling study

10.1016/s2214-109x(20)30393-4 · 2021 · External reference

Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: A systematic literature review and meta-analysis

10.1111/irv.13031 · 2023 · External reference

Epidemiologic Analysis of Respiratory Viral Infections Mainly in Hospitalized Children and Adults in a Midwest University Medical Center After the Implementation of a 14-Virus Multiplex Nucleic Acid Amplification Test

2017 · External reference

Rates of hospitalizations for respiratory syncytial virus, human metapneumovirus, and influenza virus in older adults

10.1093/infdis/jis309 · 2012 · External reference

The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates

10.1016/s1473-3099(18)30292-5 · 2018 · External reference

The road to approved vaccines for respiratory syncytial virus

10.1038/s41541-023-00734-7 · 2023 · External reference

Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults

10.1056/nejmoa2209604 · 2023 · External reference

Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults

10.1056/nejmoa2213836 · 2023 · External reference

Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults

10.1056/nejmoa2307079 · 2023 · External reference

Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants

10.1056/nejmoa2216480 · 2023 · External reference

Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention

10.1073/pnas.1115941109 · 2012 · External reference

Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera

10.1126/scitranslmed.aac4241 · 2015 · External reference

Safety and Immunogenicity of an mRNA-Based Human Metapneumovirus and Parainfluenza Virus Type 3 Combined Vaccine in Healthy Adults

10.1093/ofid/ofac206 · 2022 · External reference

A Randomized Phase 1 Clinical Trial of a Respiratory Syncytial Virus and Human Metapneumovirus Combination Protein-Based Virus-like Particle Vaccine in Adults 60-75 Years of Age

10.1093/ofid/ofaf160 · 2025 · External reference

Interprotomer disulfide-stabilized variants of the human metapneumovirus fusion glycoprotein induce high titer-neutralizing responses

2021 · External reference

Structure-based design of prefusion-stabilized human metapneumovirus fusion proteins

10.1038/s41467-022-28931-3 · 2022 · External reference

Structure-based design of a single-chain triple-disulfide-stabilized fusion-glycoprotein trimer that elicits high-titer neutralizing responses against human metapneumovirus

2023 · External reference

Efficacious human metapneumovirus vaccine based on AI-guided engineering of a closed prefusion trimer

10.1038/s41467-024-50659-5 · 2024 · External reference

Profiling of hMPV F-specific antibodies isolated from human memory B cells

10.1038/s41467-022-30205-x · 2022 · External reference

Neutralising antibodies against human metapneumovirus

2023 · External reference

Potently neutralizing and protective anti-human metapneumovirus antibodies target diverse sites on the fusion glycoprotein

10.1016/j.immuni.2022.07.003 · 2022 · External reference

Antibody recognition of the Pneumovirus fusion protein trimer interface

10.1371/journal.ppat.1008942 · 2020 · External reference

Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial

10.1016/s1473-3099(21)00200-0 · 2021 · External reference

A platform technology for generating subunit vaccines against diverse viral pathogens

10.3389/fimmu.2022.963023 · 2022 · External reference

Development of molecular clamp stabilized hemagglutinin vaccines for Influenza A viruses

10.1038/s41541-021-00395-4 · 2021 · External reference

Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus

10.1126/science.1243283 · 2013 · External reference

Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV

10.1038/nsmb.3267 · 2016 · External reference

Structure and immunogenicity of pre-fusion-stabilized human metapneumovirus F glycoprotein

10.1038/s41467-017-01708-9 · 2017 · External reference

Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency

10.1128/aac.49.11.4700-4707.2005 · 2005 · External reference

Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody

10.1126/science.1234914 · 2013 · External reference

Structural basis for antibody cross-neutralization of respiratory syncytial virus and human metapneumovirus

10.1038/nmicrobiol.2016.272 · 2017 · External reference

Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein

2015 · External reference

A recombinant human monoclonal antibody to human metapneumovirus fusion protein that neutralizes virus in vitro and is effective therapeutically in vivo

10.1128/jvi.00106-07 · 2007 · External reference

Structural basis for ultrapotent antibody-mediated neutralization of human metapneumovirus

10.1073/pnas.2203326119 · 2022 · External reference

Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract

10.1016/j.jmb.2007.02.024 · 2007 · External reference

Bacterial polysaccharide-protein conjugate vaccines

10.1093/bmb/ldh021 · 2004 · External reference

Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and Opportunities

10.3390/vaccines9121490 · 2021 · External reference

Current Developments and Challenges of mRNA Vaccines

10.1146/annurev-bioeng-110220-031722 · 2022 · External reference

Assembly of a rod-shaped chimera of a trimeric GCN4 zipper and the HIV-1 gp41 ectodomain expressed in Escherichia coli

10.1073/pnas.94.12.6065 · 1997 · External reference

Formation of highly stable chimeric trimers by fusion of an adenovirus fiber shaft fragment with the foldon domain of bacteriophage t4 fibritin

10.1074/jbc.m311791200 · 2004 · External reference

Efficacy and effectiveness of high-dose influenza vaccine in older adults by circulating strain and antigenic match: An updated systematic review and meta-analysis

2021 · External reference

An S101P substitution in the putative cleavage motif of the human metapneumovirus fusion protein is a major determinant for trypsin-independent growth in vero cells and does not alter tissue tropism in hamsters

10.1128/jvi.79.16.10678-10689.2005 · 2005 · External reference

Characterization of human metapneumovirus F protein-promoted membrane fusion: critical roles for proteolytic processing and low pH

10.1128/jvi.01287-06 · 2006 · External reference

Structural characterization of M8C10, a neutralizing antibody targeting a highly conserved prefusion-specific epitope on the metapneumovirus fusion trimerization interface

10.1128/jvi.01052-23 · 2023 · External reference

A foldon-free prefusion F trimer vaccine for respiratory syncytial virus to reduce off-target immune responses

10.1038/s41564-024-01860-1 · 2024 · External reference

Structure of a major antigenic site on the respiratory syncytial virus fusion glycoprotein in complex with neutralizing antibody 101F

10.1128/jvi.01579-10 · 2010 · External reference

Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodies

10.1038/nsmb.1950 · 2010 · External reference

Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants

10.1371/journal.pmed.0030237 · 2006 · External reference

A structural basis for antibody-mediated neutralization of Nipah virus reveals a site of vulnerability at the fusion glycoprotein apex

10.1073/pnas.1912503116 · 2019 · External reference

A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin

10.1128/jvi.00700-11 · 2011 · External reference

A method for rapid, ligation-independent reformatting of recombinant monoclonal antibodies

10.1016/j.jim.2010.02.001 · 2010 · External reference

Induction of high titred, non-neutralising antibodies by self-adjuvanting peptide epitopes derived from the respiratory syncytial virus fusion protein

10.1038/s41598-017-10415-w · 2017 · External reference

Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2

10.1002/cti2.1269 · 2021 · External reference

Combinatorial F-G Immunogens as Nipah and Respiratory Syncytial Virus Vaccine Candidates

10.3390/v13101942 · 2021 · External reference